Abstract: The invention relates to a fluid valve and fluid connection system, comprising a casing having a chamber with a first internal connection element and a first external connection element; comprising a first movable valve element in the chamber; and comprising an actuating element which has a fluid communication system with a second internal connection element and a second external connection element; wherein the first internal connection element cooperates with the second internal connection element and the valve element to establish or block a fluid connection between the first and second external connection elements.

Abstract: A tablet printing apparatus first applies either ultraviolet rays or infrared rays to surfaces of tablets that are being conveyed. The ultraviolet or infrared rays are applied to at least a contour portion of a target area where a print image is to be formed. In the case of applying ultraviolet rays, the surface of the contour portion is roughened, and the angle of contact with ink is reduced. In the case of applying infrared rays, the contour portion is etched into a recessed shape. Thereafter, ink is ejected inside the contour portion. This configuration suppresses the spread of the ejected ink to the outside of the target area. As a result, the print image has a well-defined contour.

Abstract: A portable device for cutting a capsule which has been filled with a drug formulation is configured to allow for the accurate alignment of the capsule in the capsule holder and includes a blade shaped to cut the upper portion of the capsule so as to open and dispense the drug formulation without any spillage, and the cut end is disposed capably without falling back in the medication. The device operates accurately with different capsule sizes, even with smaller capsule size when dose content is low, and provides a reliable and precise technique for splitting capsules.

Abstract: A cabinet for securely storing items includes a drawer enclosure, a drawer, a cover, an electric actuator, and a switch. The drawer is slidable at least partially into and out of the enclosure, and includes a compartment. A cover which is configured as a metal belt is designed to selectively block access to the compartments of the drawer when the cover is in a first configuration, and to allow access to the compartment when the cover is in a second configuration. The electric actuator is designed to move the cover from the first configuration to the second configuration in one of two directions. The actuator selects the direction to reduce the time required to make such movement.

Abstract: A feeding bottle apparatus comprising a cylindrical bottle for containing a flowable material, having a top with an opening, a bottom, a length, at least a first portion of the bottle curving along the length, and markings indicative of an amount of flowable material; a cap attachable to the top of the bottle, having an opening aligned with the opening of the bottle; and a tube extending through the opening of the cap and the opening of the bottle, having a first end extending out of the bottle and a second end disposed within the bottle, the first end having an opening and a deflector member, the second end extending substantially the length of the bottle and having at least one bottom member; wherein the bottle is formed of a flexible material such that pressure applied to the bottle discharges the flowable material through the tube.

Abstract: A feeding teat (40) constructed and arranged to be used on a bottle (52) that holds and dispenses a liquid to be fed to an infant or child. The teat (40) has a nipple portion (70) with an orifice (71) at a terminal end, and defines an interior profile shaped by intersecting reverse curves (75, 76) that generally decrease the interior diameter of the nipple portion (70) toward the orifice (71), so as to channel fluid flow into the orifice (112). There is a flange portion (66) constructed and arranged to be releasably coupled to the bottle (52) such that the liquid can flow from the bottle (52) into the teat (40), and a convexly shaped intermediate portion (80) integrally connecting the nipple portion (70) to the flange portion (66). A pressure relief valve (60) built into the teat (40) is constructed and arranged to admit air into the interior of at least one of the teat (40) and the bottle (52).

Abstract: The present invention provides a dental cement that exhibits excellent adhesiveness to dentin and has high mechanical strength. The present invention relates to a multi-part dental cement containing: an asymmetric acrylamide-methacrylic acid ester compound (a); an acid group-containing (meth)acrylic polymerizable monomer (b); a hydrophobic crosslinkable polymerizable monomer (c); a chemical polymerization initiator (d); and a filler (e). The asymmetric acrylamide-methacrylic acid ester compound (a) is represented by the following general formula (1): where X is an optionally substituted, linear or branched C1 to C6 aliphatic group or an optionally substituted aromatic group, the aliphatic group is optionally interrupted by at least one linking group selected from the group consisting of —O—, —S—, —CO—, —CO—O—, —O—CO—, —NR1—, —CO—NR1—, —NR1—CO—, —CO—O—NR1—, —O—CO—NR1—, and —NR1—CO—NR1—, and R1 is a hydrogen atom or an optionally substituted, linear or branched C1 to C6 aliphatic group.

Abstract: A dental cement hardened by a cement reaction involving the specific polymerizable polyacidic polymer and optionally additional crosslinkable groups, has reduced shrinkage and improved mechanical properties, in particular with regard to flexural strength and fracture toughness. Moreover, the specific polymerizable polyacidic polymer of the present invention contains a high number of acidic groups which is not reduced by the presence of polymerizable moieties, whereby water solubility of the uncured polymer is not impaired by the presence of the polymerizable moieties.

Abstract: The group of inventions relates to the field of aesthetic, plastic and reconstructive cosmetology/medicine, and more particularly to meso threads used for remedying aesthetic and age-related changes to the skin, and to methods for producing such threads. Proposed is a multicomponent meso thread consisting of a core and a shell. The core is realized in the form of a fibroin thread, and the shell contains hyaluronic acid or a salt thereof or a polyelectrolyte complex of hyaluronic acid or a salt thereof and chitosan or a salt thereof. Also proposed are a variant of the thread having a plastifying agent in the shell, and methods for producing the proposed meso threads.

Abstract: Aspects of the invention include sunscreen formulations that include uniform, rigid, spherical nanoporous calcium phosphate particles. Also provided are methods of making the sunscreen formulations. The sunscreen formulations find use in sunblocking applications.

Abstract: The present invention provides a packaged mouthwash composition, the mouthwash composition comprising an aqueous phase and an oil phase; wherein the mouthwash composition is contained within a container, the aqueous phase being present as a first bulk layer and the oil phase being present as a second bulk layer, the first and second bulk layers being in contact with one another at an interface, with one of said layers being disposed on top of the other of said layers in the container; and wherein the mouthwash composition comprises a silicone oil.

Abstract: Described herein, are aqueous soluble tin phosphate complexes formed from a mixture comprising tin (II) fluoride or tin (II) chloride and a tripolyphosphate salt, e.g., sodium tripolyphosphate (Na5P3O10), and external personal care compositions comprising the complexes, and uses thereof.

Abstract: Disclosed are oral care compositions having reduced tooth staining propensity and comprising in a pharmaceutically acceptable carrier, a cationic antimicrobial agent and an anti-stain agent comprising one or more materials from each of at least two of the following chemical groups: Group 1. anionic agents, Group 2. aldehydes, ketones, and other reactive carbonyl compounds and Group 3. nonionic ethoxylated surfactants. Examples of cationic antimicrobial agent include quaternary ammonium compounds such as cetylpyridinium chloride, cetyl pyridinium fluoride, tetradecylpyridinium chloride, N-tetradecyl-4-ethyl pyridinium chloride and domiphen bromide; chlorhexidine; and metal ion sources to supply metal ions such as stannous, zinc or copper.

Abstract: Provided are methods of treating skin with at least two alternating treatment modalities to improve the health and/or diminish signs of aging. Some methods according to the present invention may comprise topically applying at least two separate compositions, in a sequential, rotating, or alternating fashion to overcome adaptation, tolerance, or sensitization phenomena.

Abstract: A malodor-counteracting composition comprising (i) a salt of general formula (I) R1R2R3R4N+X???(I) wherein R1, R2, R3, R4 are independently selected from C1-4 alkyl, or R1, R2, R3, R4 may together constitute a nitrogen-containing cyclic system in which the nitrogen is part of a pyridinium or an imidazolinium ring; and X? is a counterion characterized by its protonated form having an acidity constant (pKa) lying between 1 and 6; and (ii) an alpha, beta-unsaturated carbonyl compound of the general formula R5R6C?CR7C(?O)YR8??(II) wherein R5, R6, R7 and R8 are independently selected from hydrogen and C1-10 hydrocarbyl residues which may be saturated, unsaturated, aromatic, cyclic, branched or unbranched, and are optionally substituted, or R5, R6, R7 and R8 may together constitute a cyclic system and Y is oxygen or a single covalent bond, with the proviso that Y is a covalent bond when R8 is hydrogen.

Abstract: An oral care composition comprising (i) basic amino acid in free or salt form, (ii) calcium carbonate, (iii) a fluoride ion source, (iv) a flavoring agent comprising less than 50% menthol, and (v) an anionic surfactant, wherein the anionic surfactant is present in an amount from 1.00 weight % to 1.39 weight % is provided.

Abstract: A transparent cosmetic or personal care composition comprising: a) a polymeric thickener, b) a protein, c) an active material, which is selected from disaccharides, lactones, inorganic salts, diacids and mixtures thereof, d) a solubilizer, e) a pH adjuster, f) a dye g) water wherein the solubilizer comprises a mixture of at least two components, said mixture comprising at least one high HLB component having an HLB value of from 10 to 20 and at least one low HLB component having an HLB value of from 1 to less than 10, and wherein the dye comprises violet, blue, red or mixtures thereof.

Abstract: The present invention relates to an antiperspirant cosmetic agent including at least one specific protein from legumes of the genus Pisum and/or Phaseolus and/or Vigna and/or Macrotyloma or from cruciferous plants of the genus Brassica and including no aluminum and/or zirconium halides and/or hydroxyhalides. The present invention further relates to the use of a specific protein and to a non-therapeutic method for reducing body perspiration. Adding or using said at least one specific protein ensures that the sweat gland(s) are effectively influenced, thus resulting in a significant reduction in axillary sweat even in the absence of antiperspirant aluminum salts.

Abstract: The invention relates to the discovery that collagenase injections are effective in dissolving and lysing the collagenase septa network in the skin that comprises cellulite. As such, the invention relates to methods of treating cellulite in a patient in need of such treatment comprising injecting or otherwise delivering the effective amount of purified collagenase to the collagenase septa network of cellulite in the skin. The invention also relates to the use of collagenase in the manufacture of a medicament to treat cellulite of the skin.

Abstract: A double conjugate molecule made of a retinoid, an organic acid, particularly an a-hydroxy acid, and an alcohol or acyl group, is provided which is useful in treating skin conditions, particularly aging. The retinoid, organic acid, and alcohol/acyl group are preferably linked via ester bonds.

Abstract: The disclosure provides personal care composition comprising guar derivative, wherein the guar derivative is chemically modified on the galactomannan polymer through an ethoxyl, propoxyl, or hydroxypropoxyl linking group with a tertiary cyclic amine compound.

Abstract: A composition includes from 40 to 80% by weight of at least one non-volatile hydrogenated polyalkylene oil; from 10 to 50% by weight of at least one tertiary-amide-terminated polyamide (ATPA) polymer; and further at least one fatty acid ester having at least one free hydroxyl group, and preferably a hydroxystearate ester. The composition is translucid.

Abstract: A method of treating the hair including providing a concentrated hair care composition in a mechanical foam dispenser. The concentrated hair care composition includes one or more silicones, from about 1% to about 5% perfume, and is substantially free of high melting point fatty compounds. The method also includes dispensing the concentrated hair care composition from the mechanical foam dispenser as a dosage of foam; applying the foam to the hair; and rinsing the foam from the hair. The foam has a density of from about 0.025 g/cm3 to about 0.3 g/cm3 when dispensed from the mechanical foam dispenser.

Abstract: Compositions for reducing skin aging are disclosed herein. The compositions can be topically applied to a skin region to reduce or prevent skin wrinkles, fine lines, thinning skin, sagging skin, skin dryness, and skin itchiness.

Abstract: The present disclosure provides formulations, methods and devices for periorbital skin rejuvenation. A periorbital skin serum in accordance with the present disclosure comprises squalane (sugarcane derived), vitamin E (tocopheryl acetate), vitamin C (tetrahexyldecyl ascorbate), and ubiquinone (coenzyme Q10, oxidized form).

Abstract: Provided is a method for increasing hair shaft diameter, the method including applying a hair care composition to a region of the hair, wherein the hair care composition includes from about 0.01% to about 10% of hops, wherein the hops is first extracted in glycerin; and from about 0.1% to about 10% of a rheology modifier.

Abstract: The present invention relates to cosmetic compositions obtained or obtainable from fish hatching fluid, methods of producing said compositions and their use in various cosmetic applications to the skin, particularly for reducing or preventing the cosmetic appearance or prevalence of wrinkles, fine lines, hyperpigmentation, laxity, dry skin, scaling and/or transepidermal water loss in skin of a mammalian animal.

Abstract: Described herein are compositions useful for moisturizing and/or improving the appearance of skin by evening skin tone and/or reducing the appearance of dark spots or hyperpigmentation. The compositions comprise cosmetic ingredients such as lactobacillus ferment; Ferula foetida root extract; Helianthus annuus (sunflower) seed extract; Terminalia ferdinandiana fruit extract, and niacinamide.

Abstract: A method of enhancing therapeutic/drug transport to the perivascular space of the brain of a patient is disclosed. In one embodiment, the method comprises the step of introducing a therapeutic/drug and an osmolyte of the present invention into a patient's cerebrospinal fluid (CSF), wherein the osmolyte is introduced to the CSF at a concentration of between 0.5 and 12.9 M (dependent on the solubility upper limit of the osmolyte), and wherein the therapeutic/drug delivery to the perivascular spaces of cerebral blood vessels and parenchyma of the central nervous system is facilitated by the presence of the osmolyte.

Abstract: The present invention relates to a topical solution comprising a retinoid or its pharmaceutically acceptable salts thereof and a process of preparing it.

Abstract: The present invention comprises compositions, methods and kits for delivering drugs. The invention provides an implantable device for delivery of a pharmaceutical substance to a patient, comprising a core comprising a core polymeric material optionally containing a core pharmaceutical substance, surrounded by a first layer comprising a first-layer pharmaceutical substance and a first-layer polymeric material, optionally surrounded by one or more additional layers comprising an additional pharmaceutical substance and an additional polymeric material, where the core, first, and optional additional polymeric materials may be the same or different, and where the optional core pharmaceutical substance, first-layer pharmaceutical substance, and optional additional pharmaceutical substances are the same or different. Implantation of the device allows a controlled release of drug for an extended period of time. The device may be implanted subcutaneously in an individual in need of continuous treatment with a drug.

Abstract: The present disclosure relates to fibers implantable in the body of a human or animal and processes for manufacturing such a fiber. The fiber undergoes a reduction in surface area to volume ratio of a factor of 1.05-10 upon injection in the human or animal body. In an embodiment, a process for manufacturing a fiber comprises extruding a biodegradable polymer into a fiber capable of fitting in a syringe needle of at least 25 Gauge, and cooling the fiber below its dry glass transition temperature while the fiber is under tension.

Abstract: Disclosed is a liposomal composition for treatment of cancer, which includes at least one PEG-Phospholipid conjugated molecule, cholesterol, and at least one phospholipid.

Abstract: Disclosed are formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs which minimize the side effects of unencapsulated non-steroidal anti-inflammatory drugs while maintaining or improving efficacy. Methods of making and administering the formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs and their use as medicaments are also provided.

Abstract: The present invention provides improved pharmaceutical formulations for the treatment of Helicobacter pylori infection and duodenal ulcer disease, and includes methods of preparation and methods of medicinal use of at least one proton pump inhibitor and at least two different antibiotics within the same solid oral dosage form, whereby at least one antibiotic is coated or encapsulated independently from at least one other antibiotic within this solid oral dosage form.

Abstract: The present invention relates to a method for preparing poloxamer-protein particles. It also relates to poloxamer-protein particles obtainable by this method, dispersion thereof, and their use in methods of encapsulation, in particular of microencapsulation.

Abstract: A gel patch includes a base fabric, an adhesive layer, and a release liner in this order, wherein the adhesive layer contains a physiologically active substance, a water-soluble (meth)acrylic polymer, water, a surfactant, and poly(methyl acrylate/2-ethylhexyl acrylate), and the surfactant comprises a polyethylene glycol fatty acid ester or a polyoxyethylene sorbitan fatty acid ester.

Abstract: A patch for a nail for treating dermatophytosis which includes a pressure-sensitive adhesive layer containing an acrylic-based pressure-sensitive adhesive and 2-(3, 5-dimethyl-1H-pyrazol-1-yl)-5-methylphenol or a salt thereof, wherein the acrylic-based pressure sensitive adhesive contains a copolymer of 2-ethylhexyl acrylate and N-vinylpyrrolidone, and wherein a mass ratio of the 2-ethylhexyl acrylate and the N-vinylpyrrolidone is 70:30 to 90:10.

Abstract: Methods of treating developmental disorders such as Angelman syndrome, Fragile X syndrome, Fragile X-associated tremor/ataxia syndrome (FXTAS), Autistic Spectrum Disorder, Autism, Asperger's syndrome, pervasive developmental disorder, Childhood Disintegrative Disorder, Rett syndrome, Landau-Kleffner Syndrome, Prader-Willi Syndrome, Tardive Dyskinesia, a seizure disorder and/or Williams Syndrome with a biguanide such as metformin, buformin, phenformin or a pharmaceutically acceptable salt thereof are provided. The methods provide therapeutic compositions that may be used to improve one or more symptoms of the developmental disorder.

Abstract: A method of forming an implant in the tissue can include: providing an injectable composition having a neat liquid carrier, wherein the neat liquid carrier is substantially liquid at room temperature and/or about body temperature; and injecting the neat liquid solution into the tissue at the rate of 10-12000 injections per minute and/or at an amount of 1.0E-02 ml to 1.0E-16 ml per needle per injection. The neat liquid carrier can be polymeric or non-polymeric. The neat liquid carrier can be biodegradable. The neat liquid carrier can include a viscosity-modifying agent. The injecting can form an implant with area greater than or equal to 5 mm2. The neat liquid carrier can be injected at a depth of 10 microns to 5 mm. The neat liquid solution can include a drug or other agent.

Abstract: Methods, systems, devices, and medicaments are provided for locally administering to a pelvic-area organ or tissue structure in a patient at least one drug continuously or continually over a treatment period of 24 hours or more in an amount effective to achieve a therapeutic effect in another organ or tissue structure by means of shared or convergent pelvic afferent pathways. The methods systems, devices, and medicaments can be used in the treatment of IC/BPS, chronic pelvic pain, vulvodynia, orchialgia, urethral syndrome, dysparenia, chronic prostatitis, chronic pelvic pain, levator ani syndrome, irritative bowel syndrome, or a combination thereof. The drug may include anesthetic agents, analgesic agents, antispasmodic agents, antimuscarinic agents, and combinations thereof. The drug may be released from a drug delivery device or a sustained release composition deployed inside the bladder.

Abstract: Disclosed herein are methods for treating cancer comprising administering at least one immune checkpoint inhibitor and at least one Retinoic Acid Receptor or Retinoid X Receptor active agent.

Abstract: The present disclosure is directed to compositions and methods for treating osteoarthritis comprising increasing the expression of Dnmt3b and/or inhibiting aminobutyrate aminotransferase.

Abstract: In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, and Z are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.

Abstract: Provided herein are methods, compositions, and systems for treating mitochondrial disorders (e.g., MERRF, MELAS, Kearns-Sayre syndrome, chronic progressive external ophthalmoplegia, diabetes mellitus and deafness, lactic acidosis, Leber's hereditary optic neuropathy, Wolff-Parkinson-White syndrome, Leigh syndrome, NARP, myoneurogenic gastrointestinal encephalopathy, mitochondrial DNA depletion syndrome) or neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease) by administering aspartate, or an analog or prodrug thereof, or an agent that increases intracellular levels of aspartate. Pharmaceutical compositions and kits for use in treating mitochondrial disorders and neurodegenerative diseases are also described herein. Also provided are methods for treating disease by modulating the redox state of a cell, and methods of treating a proliferative disease by administering a cytosolic aspartate aminotransferase (GOT1) inhibitor.

Abstract: Provided herein are compositions comprising eicosapentaenoic acid (EPA) and polar lipids (e.g., glycolipids and phospholipids), and which do not contain any docosahexaenoic acid (DHA) or esterified fatty acids.

Abstract: The present invention relates to a topical pharmaceutical composition comprising acitretin and a process for its preparation. It also relates to a method of treating skin disorders by administering said topical pharmaceutical composition.

Abstract: The present invention provides topical dermal compositions including microsphere encapsulated isotretinoin. Pharmaceutically acceptable salts, esters, or amides of isotretinoin are also contemplated for use in the practice of the invention. The compositions of the invention are useful for treating a variety of conditions associated with excess sebum production, such as, for example, acne.

Abstract: The present invention relates to the method of lowering cholesterol in a patient in need thereof by administering to said patient a therapeutic effective amount of a compound selected from the group consisting of 1-alkyl, 2-acyl-glyceraldehyde-3-phosphate (G3P), 1-alkyl, 2-acyl glycerol and 1-alkyl, 2-acyl-glycerylphosphatidylethanolamine (GPE) or a pharmaceutically acceptable salt thereof.

Abstract: Pharmacological compositions containing a hydroxamic acid derivative selected from (2S)-2-((4-((4-((1S)-1,2-dihydroxyethyl)phenyl)ethynyl)benzoyl)(methyl)amino)-N-hydroxy-N?,2-dimethylmalonamide, (2S)-2-((4-((4-((1R)-1,2-dihydroxyethyl)phenyl)ethynyl)benzoyl)(methyl)amino)-N-hydroxy-N?,2-dimethylmalonamide, and (2S)—N-hydroxy-2-((4-((4-((1S)-1-hydroxy-2-methoxyethyl)phenyl)ethynyl)benzoyl)(methyl)amino)-N?,2-dimethylmalonamide, or a salt of said derivatives, and an antibiotic substance are useful in the treatment of gram-negative bacterial infections.